| LDR | 01193cam a2200277 i 4500 | ||
| 001 | 002939732 | ||
| 003 | MiAaHDL | ||
| 005 | 20110215000000.0 | ||
| 006 | m d | ||
| 007 | cr bn ---auaua | ||
| 008 | 770602s1976 dcu f000 0 eng | ||
| 010 | ⊔ | ⊔ | ‡a 77601116 |
| 035 | ⊔ | ⊔ | ‡asdr-pur1385765 |
| 035 | ⊔ | ⊔ | ‡asdr-miu.990029397320106381 |
| 035 | ⊔ | ⊔ | ‡a1385765 |
| 035 | ⊔ | ⊔ | ‡a(OCoLC)2830119 |
| 040 | ⊔ | ⊔ | ‡aDLC ‡cDLC ‡dOCL |
| 043 | ⊔ | ⊔ | ‡an-us--- |
| 049 | ⊔ | ⊔ | ‡aIPL1 |
| 050 | 0 | ⊔ | ‡aKF27 ‡b.G664 1976a |
| 082 | 0 | ⊔ | ‡a353.007/7 |
| 086 | 0 | ⊔ | ‡aY 4.G 74/7:D 84/13 |
| 110 | 1 | ⊔ | ‡aUnited States. ‡bCongress. ‡bHouse. ‡bCommittee on Government Operations. ‡bIntergovernmental Relations and Human Resources Subcommittee. |
| 245 | 1 | 0 | ‡aFDA's regulation of the drug "triazure" : ‡bhearing before a Subcommittee of the Committee on Government Operations, House of Representatives, Ninety-fourth Congress, second session. October 27, 1976. |
| 260 | ⊔ | ⊔ | ‡aWashington : ‡bU.S. Govt. Print. Off. : ‡b[For sale by the Supt. of Docs., U.S. G.P.O., Congressional Sales Office], ‡c1976. |
| 300 | ⊔ | ⊔ | ‡av, 212 p. ; ‡c24 cm. |
| 538 | ⊔ | ⊔ | ‡aMode of access: Internet. |
| 610 | 1 | 0 | ‡aUnited States. ‡bFood and Drug Administration. |
| 650 | ⊔ | 0 | ‡aPsoriasis ‡xChemotherapy. |
| 650 | ⊔ | 0 | ‡aAzaribine. |
| CID | ⊔ | ⊔ | ‡a002939732 |
| DAT | 0 | ⊔ | ‡a20101014121438.0 ‡b20110215000000.0 |
| DAT | 1 | ⊔ | ‡a20120815064345.0 ‡b2023-06-28T18:26:22Z |
| CAT | ⊔ | ⊔ | ‡aSDR-PUR ‡dUNKNOWN ‡lloader.pl-001-001 |
| FMT | ⊔ | ⊔ | ‡aBK |
| HOL | ⊔ | ⊔ | ‡0sdr-pur1385765 ‡apur1 ‡bSDR ‡cPUR ‡ppur1.32754075430987 ‡sPUR ‡11385765 |
| 974 | ⊔ | ⊔ | ‡bPUR ‡cPUR ‡d20230628 ‡sgoogle ‡upur1.32754075430987 ‡y1976 ‡rpd ‡qbib ‡tUS fed doc |
| 974 | ⊔ | ⊔ | ‡bMIU ‡cMIU ‡d20241120 ‡sgoogle ‡umdp.39015081178561 ‡y1976 ‡rpd ‡qbib ‡tUS fed doc |